JP6519038B2 - 脳梗塞治療のための多能性幹細胞 - Google Patents

脳梗塞治療のための多能性幹細胞 Download PDF

Info

Publication number
JP6519038B2
JP6519038B2 JP2014035725A JP2014035725A JP6519038B2 JP 6519038 B2 JP6519038 B2 JP 6519038B2 JP 2014035725 A JP2014035725 A JP 2014035725A JP 2014035725 A JP2014035725 A JP 2014035725A JP 6519038 B2 JP6519038 B2 JP 6519038B2
Authority
JP
Japan
Prior art keywords
cells
negative
cell
pluripotent stem
cell preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014035725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015159895A5 (enExample
JP2015159895A (ja
Inventor
正順 吉田
正順 吉田
真理 出澤
真理 出澤
悌二 冨永
悌二 冨永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Life Science Institute Ltd
Original Assignee
Tohoku University NUC
Life Science Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, Life Science Institute Ltd filed Critical Tohoku University NUC
Priority to JP2014035725A priority Critical patent/JP6519038B2/ja
Priority to US14/695,843 priority patent/US20160082048A1/en
Publication of JP2015159895A publication Critical patent/JP2015159895A/ja
Priority to US15/413,086 priority patent/US10993966B2/en
Publication of JP2015159895A5 publication Critical patent/JP2015159895A5/ja
Application granted granted Critical
Publication of JP6519038B2 publication Critical patent/JP6519038B2/ja
Priority to US17/219,430 priority patent/US20210213068A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2014035725A 2014-02-25 2014-02-26 脳梗塞治療のための多能性幹細胞 Active JP6519038B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2014035725A JP6519038B2 (ja) 2014-02-26 2014-02-26 脳梗塞治療のための多能性幹細胞
US14/695,843 US20160082048A1 (en) 2014-02-26 2015-04-24 Pluripotent stem cell for treatment of cerebral infarction
US15/413,086 US10993966B2 (en) 2014-02-26 2017-01-23 Pluripotent stem cell for treatment of cerebral infarction
US17/219,430 US20210213068A1 (en) 2014-02-25 2021-03-31 Pluripotent stem cell for treatment of cerebral infarction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014035725A JP6519038B2 (ja) 2014-02-26 2014-02-26 脳梗塞治療のための多能性幹細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018074932A Division JP6604492B2 (ja) 2018-04-09 2018-04-09 脳梗塞治療のための多能性幹細胞

Publications (3)

Publication Number Publication Date
JP2015159895A JP2015159895A (ja) 2015-09-07
JP2015159895A5 JP2015159895A5 (enExample) 2017-02-09
JP6519038B2 true JP6519038B2 (ja) 2019-05-29

Family

ID=54183439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014035725A Active JP6519038B2 (ja) 2014-02-25 2014-02-26 脳梗塞治療のための多能性幹細胞

Country Status (2)

Country Link
US (3) US20160082048A1 (enExample)
JP (1) JP6519038B2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6391364B2 (ja) * 2014-08-25 2018-09-19 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
CA3011333C (en) * 2016-01-15 2022-01-25 University Of Toyama Mobilization of pluripotent stem cells for ischemic cerebral infarction
WO2017199976A1 (ja) * 2016-05-16 2017-11-23 国立大学法人名古屋大学 多能性幹細胞による周産期脳障害の改善及び治療
EP3492091B1 (en) * 2016-07-29 2021-07-14 Tohoku University "muse" cells as prophylactic or therapeutic agent for aneurysm
EP3494979B1 (en) * 2016-08-03 2025-07-09 Yabuki, Hiroshi Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
WO2018025973A1 (ja) * 2016-08-03 2018-02-08 国立大学法人名古屋大学 多能性幹細胞による慢性肺疾患の改善及び治療
JP7089283B2 (ja) 2016-08-30 2022-06-22 国立大学法人 新潟大学 細胞製剤および細胞製剤の製造方法
SG11201912831TA (en) * 2017-06-20 2020-01-30 Univ Nagoya Nat Univ Corp Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells
JP6604492B2 (ja) * 2018-04-09 2019-11-13 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
CN110772535A (zh) * 2018-07-12 2020-02-11 南通大学 多系分化持续应激细胞在制备镇痛药物中的应用
JP7618233B2 (ja) * 2019-08-09 2025-01-21 国立大学法人東北大学 脳血管性認知症の治療または予防剤
CN110693908A (zh) * 2019-10-15 2020-01-17 南通大学 多系分化持续应激细胞的应用、治疗周围神经损伤药物及其制备方法
JP7658917B2 (ja) * 2020-01-08 2025-04-08 公益財団法人神戸医療産業都市推進機構 身体機能回復促進剤
WO2021201286A1 (ja) 2020-04-02 2021-10-07 国立大学法人東北大学 ハイポテンシャル多能性幹細胞
JP2025123077A (ja) * 2024-02-09 2025-08-22 国立大学法人東北大学 脊髄梗塞治療のための多能性幹細胞

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue

Also Published As

Publication number Publication date
US20160082048A1 (en) 2016-03-24
US20170128494A1 (en) 2017-05-11
US10993966B2 (en) 2021-05-04
JP2015159895A (ja) 2015-09-07
US20210213068A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
JP6519038B2 (ja) 脳梗塞治療のための多能性幹細胞
JP5872041B2 (ja) 幹細胞由来微小胞を含む神経生成促進用組成物
JP2013508013A (ja) 細胞療法戦略を用いた慢性神経組織損傷の治療方法
WO2014027684A1 (ja) 心筋梗塞の修復再生を誘導する多能性幹細胞
JP6401757B2 (ja) 臍帯血細胞を用いた脳損傷の処置
JP2015160820A (ja) 慢性腎障害治療のための多能性幹細胞
JP6604492B2 (ja) 脳梗塞治療のための多能性幹細胞
JP7255805B2 (ja) 多能性幹細胞による胎児発育不全に伴う脳障害の改善及び治療
JP7072777B2 (ja) 慢性腎障害治療のための多能性幹細胞
JP6994200B2 (ja) 多能性幹細胞による周産期脳障害の改善及び治療
JP7076709B2 (ja) 間葉系幹細胞活性化剤
US20210228638A1 (en) Therapeutic agent for spinal cord injury
JP7618233B2 (ja) 脳血管性認知症の治療または予防剤
Genc et al. Effects of mesenchymal stromal cells on the neuropathic pain induced by chronic constriction injury in rats
WO2025170054A1 (ja) 脊髄梗塞治療のための多能性幹細胞
Bertuzzi et al. Stem cell’s behavioral effects in rats in a model of Alzheimer’s disease
US20250295703A1 (en) Treatment agent for hair damage
JP2023041486A (ja) 毛髪損傷の治療剤
WO2021085639A1 (ja) 多能性幹細胞による間質性膀胱炎の治療
Ourique et al. Advances in Stem Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20171201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180704

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6519038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250